Review on the Use of Nanofillers in Polyurethane Coating Systems for Different Coating Applications

Polyurethane (PU) is the most common, versatile and researched material in the world. It is widely used in many applications such as medical, automotive and industrial fields. It can be found in products such as furniture, coatings, adhesives, construction materials, Paints, elastomers, insulators, elastic fibres, foams, integral skins, etc. because it has extraordinary properties and the facility to tailor-made various formulations according to property requirement using different raw materials which are available. Though the material is having fascinating properties the material is also associated with various problems such as inferior coating properties. Inorganic pigments and fillers are dispersed in organic components and binders to improve different properties of the coating. This paper is intended to review the various nanofillers used in different PU coating systems. It gives a general introduction about the various fillers and it's classification, Mechanism by which the filler enhances the mechanical properties of the materials, various factors which affect the properties of the coatings. Various methods of incorporation of fillers in the coating systems are discussed. Various nanofillers such as SiO2(Silicon Dioxide), TiO2(Titanium Dioxide), AL2O3(Aluminium Oxide), antimony doped tin oxide (ATO), BaSO4(Barium Sulphate), FE2O3(Ferric Oxide) as well as carbon nanotubes, graphene derived fillers and nano-diamonds are discussed in detail. The importance and effect of surface modification of fillers to enhance coating properties are also discussed along with challenges associated with polyurethane coatings and future trends

OPTIMIZATION OF FORMULATION AND DEVELOPMENT OF CARROT FORTIFIED IDLI AND ITS PHYSICO-CHEMICAL CHARACTERIZATION

Idli is one of the most important balanced breakfast foods in India and the other countries. The present study was undertaken to determine the enhancement of nutritional value of idli by fortification of carrot in idli batter. Idli were prepared from rice and black gram the ratio 3:1 was constant and fortification of carrot at 5%, 10%, 15% and 20% after fermentation. The developed idli were analyzed for physicochemical properties, organoleptic evaluation and nutritive value of the idli. The result revealed that 10% fortification of carrot was accepted in the terms of sensory evaluation and nutritional value would make it as a complete balanced breakfast food for all age groups of peopl

Use of the Cassette-Dosing Approach to Assess Brain Penetration in Drug Discovery

ABSTRACT: The objective of the present study was to examine the cassette dosing method in determination of brain-to-plasma concentration ratio (area under the concentration-time profiles for plasma/area under the concentration-time profiles for brain, K p ). Eleven model compounds, amprenavir, citalopram, digoxin, elacridar, imatinib, (3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1,2:1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester (Ko143), loperamide, prazosin, quinidine, sulfasalazine, and verapamil, were selected to compare their K p determined from discrete dosing in wild-type mice and their K p from cassette dosing in wild-type, Mdr1a/1b(؊/؊), Bcrp1(؊/؊), and Mdr1a/1b(؊/؊)/Bcrp1(؊/؊) mice at 1 to 3 mg/kg. The mice brain and plasma were collected at 0.25, 1, and 3 h and were analyzed using high-performance liquid chromatography-tandem mass spectrometry methods. The K p determined from discrete dosing versus cassette dosing in the wild-type mice were within 2-fold for all the compounds except sulfasalazine and Ko143. The brain concentrations of sulfasalazine and Ko143 and the plasma concentrations of Ko143 were below the lower limit of quantitation. In addition, the K p values estimated by mass spectrometry responses, namely the ratio of compound peak area to internal standard peak area, were within 2-fold of the K p observed from the actual concentrations. Furthermore, the ratios of K p in Mdr1a/1b(؊/؊), Bcrp1(؊/؊), and Mdr1a/1b(؊/؊)/ Bcrp1(؊/؊) mice versus the K p in the wild-type mice from cassette dosing were consistent with the ones reported in the literature where the compounds were dosed discretely. These results demonstrate that drug-drug interactions at the blood-brain barrier are unlikely at a subcutaneous dose of 1 to 3 mg/kg and support the use of the cassette dosing approach to assess brain penetration in drug discovery

GluN2A NMDA Receptor Enhancement Improves Brain Oscillations, Synchrony, and Cognitive Functions in Dravet Syndrome and Alzheimer's Disease Models.

NMDA receptors (NMDARs) play subunit-specific roles in synaptic function and are implicated in neuropsychiatric and neurodegenerative disorders. However, the in vivo consequences and therapeutic potential of pharmacologically enhancing NMDAR function via allosteric modulation are largely unknown. We examine the in vivo effects of GNE-0723, a positive allosteric modulator of GluN2A-subunit-containing NMDARs, on brain network and cognitive functions in mouse models of Dravet syndrome (DS) and Alzheimer's disease (AD). GNE-0723 use dependently potentiates synaptic NMDA receptor currents and reduces brain oscillation power with a predominant effect on low-frequency (12-20 Hz) oscillations. Interestingly, DS and AD mouse models display aberrant low-frequency oscillatory power that is tightly correlated with network hypersynchrony. GNE-0723 treatment reduces aberrant low-frequency oscillations and epileptiform discharges and improves cognitive functions in DS and AD mouse models. GluN2A-subunit-containing NMDAR enhancers may have therapeutic benefits in brain disorders with network hypersynchrony and cognitive impairments

Neurodevelopmental disorders in children aged 2-9 years: Population-based burden estimates across five regions in India.

BACKGROUND: Neurodevelopmental disorders (NDDs) compromise the development and attainment of full social and economic potential at individual, family, community, and country levels. Paucity of data on NDDs slows down policy and programmatic action in most developing countries despite perceived high burden. METHODS AND FINDINGS: We assessed 3,964 children (with almost equal number of boys and girls distributed in 2-<6 and 6-9 year age categories) identified from five geographically diverse populations in India using cluster sampling technique (probability proportionate to population size). These were from the North-Central, i.e., Palwal (N = 998; all rural, 16.4% non-Hindu, 25.3% from scheduled caste/tribe [SC-ST] [these are considered underserved communities who are eligible for affirmative action]); North, i.e., Kangra (N = 997; 91.6% rural, 3.7% non-Hindu, 25.3% SC-ST); East, i.e., Dhenkanal (N = 981; 89.8% rural, 1.2% non-Hindu, 38.0% SC-ST); South, i.e., Hyderabad (N = 495; all urban, 25.7% non-Hindu, 27.3% SC-ST) and West, i.e., North Goa (N = 493; 68.0% rural, 11.4% non-Hindu, 18.5% SC-ST). All children were assessed for vision impairment (VI), epilepsy (Epi), neuromotor impairments including cerebral palsy (NMI-CP), hearing impairment (HI), speech and language disorders, autism spectrum disorders (ASDs), and intellectual disability (ID). Furthermore, 6-9-year-old children were also assessed for attention deficit hyperactivity disorder (ADHD) and learning disorders (LDs). We standardized sample characteristics as per Census of India 2011 to arrive at district level and all-sites-pooled estimates. Site-specific prevalence of any of seven NDDs in 2-<6 year olds ranged from 2.9% (95% CI 1.6-5.5) to 18.7% (95% CI 14.7-23.6), and for any of nine NDDs in the 6-9-year-old children, from 6.5% (95% CI 4.6-9.1) to 18.5% (95% CI 15.3-22.3). Two or more NDDs were present in 0.4% (95% CI 0.1-1.7) to 4.3% (95% CI 2.2-8.2) in the younger age category and 0.7% (95% CI 0.2-2.0) to 5.3% (95% CI 3.3-8.2) in the older age category. All-site-pooled estimates for NDDs were 9.2% (95% CI 7.5-11.2) and 13.6% (95% CI 11.3-16.2) in children of 2-<6 and 6-9 year age categories, respectively, without significant difference according to gender, rural/urban residence, or religion; almost one-fifth of these children had more than one NDD. The pooled estimates for prevalence increased by up to three percentage points when these were adjusted for national rates of stunting or low birth weight (LBW). HI, ID, speech and language disorders, Epi, and LDs were the common NDDs across sites. Upon risk modelling, noninstitutional delivery, history of perinatal asphyxia, neonatal illness, postnatal neurological/brain infections, stunting, LBW/prematurity, and older age category (6-9 year) were significantly associated with NDDs. The study sample was underrepresentative of stunting and LBW and had a 15.6% refusal. These factors could be contributing to underestimation of the true NDD burden in our population. CONCLUSIONS: The study identifies NDDs in children aged 2-9 years as a significant public health burden for India. HI was higher than and ASD prevalence comparable to the published global literature. Most risk factors of NDDs were modifiable and amenable to public health interventions